Moving avidence into action
This document is part of a series of briefs for health program managers interested in implementing evidence-based programs. With a special emphasis on underutilized interventions, they present evidence on programs that work and provide guidance and resources for replicat...ion.
more
PLOS ONE | DOI:10.1371/journal.pone.0142290 November 9, 2015; 1 / 16
Research
Emerging Infectious Diseases Vol. 12, No. 5, May 2006
HIV/TB Research Meeting; March 3, 2013
PLOS ONE | DOI:10.1371/journal.pone.0155525 May 19, 2016, 1 / 11
Review
S Afr Med J 2014;104(3):174-177. DOI: 10.7196/SAMJ.7968
Research Article
BMC Infectious Diseases 2014, 14:91/1471-2334/14/91
Профілактичне лікування ізоніазидом. Що це таке?
The present Consolidated guidelines include a comprehensive set of WHO recommendations for the treatment and care of DR-TB, derived from these WHO guidelines documents. The consolidated guidelines include policy recommendations on treatment regimens for isoniazid-resistant TB (Hr-TB) and MDR/RR-TB, ...including longer and shorter regimens, culture monitoring of patients on treatment, the timing of antiretroviral therapy (ART) in MDR/RR-TB patients infected with the human immunodeficiency virus (HIV), use of surgery for patients receiving MDR-TB treatment, and optimal models of patient support and care.
more
PLoSONE 12(9):e0184986.https://doi.org/10.1371/journal.pone.0184986
The new WHO recommendations for the treatment of isoniazid-resistant, rifampicin-susceptible TB are based upon a review of evidence from patients treated with such regimens by a Guideline Development Group in conformity with WHO requirements for evidence-based policies.
Of the more than 10 million people estimated to have fallen ill with tuberculosis (TB) in 2022, just over 400 000 people developed TB resistant to rifampicin (RIF), and 1.3 million people developed TB resistant isoniazid (INH). Drug resistance must be detected rapidly and accurately to initiate appr...opriate and effective treatment.
more